Alkermes plc

ALKS

$30.95

Name : Alkermes plc

Sector : Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Mark. Cap: $5,109,163,520.00

EPSttm : 2.07

Alkermes plc

$30.95

0.13%

$0.04

Float Short %

9.35

Margin Of Safety %

-14

Put/Call OI Ratio

0.4

EPS Next Q Diff

-0.12

EPS Last/This Y

-0.47

EPS This/Next Y

-0.22

Price

30.95

Target Price

41.71

Analyst Recom

1.53

Performance Q

3.24

Relative Volume

0.54

Beta

0.53

Ticker: ALKS

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-08	ALKS	28.44	0.86	1.11	25821
2025-09-09	ALKS	27.83	0.75	7.07	31681
2025-09-10	ALKS	26.91	0.88	1.30	34130
2025-09-11	ALKS	27.72	0.88	0.22	34160
2025-09-12	ALKS	26.97	0.88	1.58	34238
2025-09-15	ALKS	26.55	0.88	1.40	34207
2025-09-16	ALKS	27.4	0.86	23.24	34022
2025-09-17	ALKS	27.87	0.8275258465073	3.5862068965517	33409
2025-09-18	ALKS	28.55	0.79	30.76	32774
2025-09-19	ALKS	27.79	0.75	0.33	32113
2025-09-22	ALKS	27.63	1.30	0.02	7702
2025-09-23	ALKS	27.75	0.84	0.52	9563
2025-09-24	ALKS	27.83	0.84	0.45	9669
2025-09-25	ALKS	27.13	0.83	1.50	9775
2025-09-26	ALKS	27.87	0.84	0.01	9821
2025-09-29	ALKS	29.06	0.48	1.56	13838
2025-09-30	ALKS	30.14	0.48	0.05	13870
2025-10-01	ALKS	30.66	0.45	0.03	14365
2025-10-02	ALKS	31.27	0.45	0.05	14385
2025-10-03	ALKS	31.07	0.38	2.64	16374
2025-10-06	ALKS	30.99	0.40	0.54	16560
2025-10-07	ALKS	30.94	0.40	0.83	16716
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-08	ALKS	28.45	-47.4	-116.9	1.70
2025-09-09	ALKS	27.84	-47.1	-105.7	1.73
2025-09-10	ALKS	26.93	-47.3	-110.5	1.75
2025-09-11	ALKS	27.71	-47.3	-85.1	1.75
2025-09-12	ALKS	26.96	-47.3	-108.1	1.75
2025-09-15	ALKS	26.52	-47.3	-103.8	1.75
2025-09-16	ALKS	27.39	-47.3	-83.5	1.75
2025-09-17	ALKS	27.89	-47.3	-89.5	1.75
2025-09-18	ALKS	28.57	-47.3	-86.8	1.75
2025-09-19	ALKS	27.79	-47.3	-107.9	1.75
2025-09-22	ALKS	27.63	-47.3	-99.4	1.75
2025-09-23	ALKS	27.75	-47.3	-95.1	1.75
2025-09-24	ALKS	27.83	-47.3	-95.9	1.75
2025-09-25	ALKS	27.13	-47.3	-107.0	1.75
2025-09-26	ALKS	27.89	-47.3	-85.5	1.75
2025-09-29	ALKS	29.06	-47.3	-79.9	1.75
2025-09-30	ALKS	30.01	-47.3	-83.6	1.75
2025-10-01	ALKS	30.66	-47.3	-88.2	1.75
2025-10-02	ALKS	31.29	-47.3	-88.7	1.75
2025-10-03	ALKS	31.07	-47.3	-99.4	1.75
2025-10-06	ALKS	30.99	-47.3	-100.5	1.75
2025-10-07	ALKS	30.95	-47.3	-97.5	1.75
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-08	ALKS	-0.15	-2.05	8.59
2025-09-09	ALKS	-0.15	-2.05	8.59
2025-09-10	ALKS	-0.15	-2.05	8.59
2025-09-11	ALKS	-0.15	-2.05	8.28
2025-09-12	ALKS	-0.15	-2.05	8.28
2025-09-15	ALKS	-0.15	-2.05	8.28
2025-09-16	ALKS	-0.15	-2.05	8.28
2025-09-17	ALKS	-0.15	-2.05	8.28
2025-09-18	ALKS	-0.15	-2.05	8.28
2025-09-19	ALKS	-0.15	-2.05	8.28
2025-09-22	ALKS	-0.15	-2.08	8.28
2025-09-23	ALKS	-0.15	-2.08	8.28
2025-09-24	ALKS	-0.15	-2.08	8.28
2025-09-25	ALKS	-0.15	-2.08	9.37
2025-09-26	ALKS	-0.15	-2.08	9.37
2025-09-29	ALKS	-0.15	-2.08	9.35
2025-09-30	ALKS	-0.16	-2.08	9.35
2025-10-01	ALKS	-0.16	-2.08	9.35
2025-10-02	ALKS	-0.16	-2.08	9.35
2025-10-03	ALKS	-0.16	-2.08	9.35
2025-10-06	ALKS	-0.16	-2.07	9.35
2025-10-07	ALKS	-0.16	-2.07	9.35
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

0.52

Avg. EPS Est. Current Quarter

0.38

Avg. EPS Est. Next Quarter

0.4

Insider Transactions

-0.16

Institutional Transactions

-2.07

Beta

0.53

Average Sales Estimate Current Quarter

355

Average Sales Estimate Next Quarter

366

Fair Value

26.73

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

15.1

Max Drawdown 5-Year %

-33.2

Target Price

41.71

P/E

14.86

Forward P/E

19.75

PEG

P/S

3.39

P/B

3.14

P/Free Cash Flow

10.65

EPS

2.08

Average EPS Est. Cur. Y

1.75

EPS Next Y. (Est.)

1.53

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

23.15

Relative Volume

0.54

Return on Equity vs Sector %

-3.7

Return on Equity vs Industry %

13.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

-97.5

Alkermes plc

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1800

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

stock quote shares ALKS – Alkermes plc Stock Price stock today

news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025

marketwatch ALKS – Alkermes plc yahoo finance google finance

stock history ALKS – Alkermes plc invest stock market

stock prices ALKS premarket after hours

ticker ALKS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ALKS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y